| Investigational hMPV/RSV vaccine | Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older | Phase 2 | Active not recruiting | 1,530 | Jan 18, 2027 |
| ALTUVIIIO | Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A | Phase 3 | Active not recruiting | 261 | Jan 15, 2027 |
| SP0289 | Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | Phase 2 | Active not recruiting | 720 | Dec 1, 2026 |
| PCV21 | Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents | Phase 3 | Active not recruiting | 1,268 | Dec 1, 2026 |
| balinatunfib | A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) | Phase 2 | Terminated | 7 | Sep 29, 2026 |
| Amlitelimab | Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study | Phase 2 | Terminated | 335 | Sep 22, 2026 |
| Qfitlia | Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX | Phase 3 | Completed | 281 | Sep 14, 2026 |
| Itepekimab (SAR440340) | A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD | Phase 3 | Completed | 669 | Sep 10, 2026 |
| SAR441566 | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis | Phase 2 | Terminated | 170 | Aug 6, 2026 |
| Amlitelimab | A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease | Phase 2 | Active not recruiting | 229 | Aug 5, 2026 |
| Qfitlia | Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B | Phase 3 | Completed | 32 | Aug 4, 2026 |
| SAR441566 | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. | Phase 2 | Terminated | 105 | Jul 30, 2026 |
| SAR441344 IV | Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Phase 2 | Active not recruiting | 109 | Jul 10, 2026 |
| Amlitelimab | A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis | Phase 3 | Active not recruiting | 1,541 | Jun 29, 2026 |
| Dupilumab | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) | Phase 3 | Completed | 138 | Jun 8, 2026 |
| Dupilumab | A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 1) | Phase 3 | Completed | 142 | Jun 8, 2026 |
| Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 | A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older | Phase 2 | Completed | 1,162 | May 22, 2026 |
| AK112 | A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase 2 | Active not recruiting | 254 | May 15, 2026 |
| Dupilumab | A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab)) | Phase 2 | Active not recruiting | 68 | May 15, 2026 |
| venglustat | A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease | Phase 3 | Active not recruiting | 104 | May 15, 2026 |
| MenACYW conjugate vaccine | Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in China | Phase 3 | Completed | 1,602 | May 1, 2026 |
| IIV-HD | Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older | Phase 2 | Completed | 980 | Apr 16, 2026 |
| RIV (recombinant influenza vaccine) | Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older | Phase 2 | Completed | 980 | Apr 3, 2026 |
| Itepekimab (SAR440340) | A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps | Phase 2 | Completed | 66 | Mar 31, 2026 |
| SP0289 | Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older | Phase 2 | Completed | 276 | Mar 24, 2026 |
| — | Actual Use Trial of Tadalafil 5 mg | Phase 3 | Completed | 2,212 | Mar 2, 2026 |
| SQIN-Furosemide | Use of a Novel SUBCUTaneous Preparation of Furosemide to Facilitate Early Supported Discharge of Patients With Heart Failure | Phase 2 | Completed | 172 | Mar 1, 2026 |
| RSV/hMPV vaccine candidate Dose L | Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate | Phase 2 | Completed | 646 | Feb 27, 2026 |
| Lunsekimig | Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma | Phase 2 | Completed | 685 | Feb 23, 2026 |
| Lunsekimig | A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis | Phase 2 | Completed | 150 | Feb 12, 2026 |
| Sarclisa | Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | Phase 3 | Completed | 514 | Jan 30, 2026 |
| lunsekimig | A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps | Phase 2 | Completed | 79 | Jan 29, 2026 |
| Yellow fever vaccine (live) | Phase 3 Randomized, Modified Double-blind, Active-controlled Safety Study on vYF in Adults | Phase 3 | Completed | 640 | Jan 20, 2026 |
| Insulin | Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes | Phase 2 | Completed | 114 | Jan 20, 2026 |
| NVX-CoV2705 | Safety and Immunogenicity of NVX-CoV2705 | Phase 3 | Completed | 676 | Jan 12, 2026 |
| Eliglustat GZ385660 | Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3 | Phase 3 | Completed | 57 | Dec 26, 2025 |
| Yellow fever vaccine (live) | Phase 3 Single Arm, Open Study on vYF in Adults | Phase 3 | Completed | 254 | Dec 25, 2025 |
| Nicoderm | Adaptive Use of Nicotine Substitution to Maintain Smoking Reduction/Abstinence in Nicotine Responders | Phase 3 | Completed | 150 | Dec 9, 2025 |
| RSVt Vaccine | Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers | Phase 3 | Terminated | 6,300 | Dec 4, 2025 |
| Amlitelimab | A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) | Phase 3 | Completed | 589 | Nov 25, 2025 |